Dulaglutide (Trulicity) studies: 418 papers with results
Page 3 of 9
- Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with Type 2 diabetes: dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study.
Grunberger G · Diabetic medicine : a journal of the British Diabetic Association · 2012
Randomized controlled trial · 7 results
- LY2189265, a long-acting glucagon-like peptide-1 analogue, showed a dose-dependent effect on insulin secretion in healthy subjects.
Barrington P · Diabetes, obesity & metabolism · 2011
Randomized controlled trial · 10 results
- Dulaglutide reduces binge episodes in type 2 diabetic patients with binge eating disorder: A pilot study.
Da Porto A · Diabetes & metabolic syndrome · 2020
Randomized controlled trial · 5 results
- Dose-finding results in an adaptive, seamless, randomized trial of once-weekly dulaglutide combined with metformin in type 2 diabetes patients (AWARD-5).
Skrivanek Z · Diabetes, obesity & metabolism · 2014
Randomized controlled trial · 6 results
- Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide significantly decreases glycated haemoglobin compared with once-daily liraglutide in Japanese patients with type 2 diabetes: 52 weeks of treatment in a randomized phase III study.
Odawara M · Diabetes, obesity & metabolism · 2016
Randomized controlled trial · 11 results
- Efficacy of dulaglutide on vascular health indexes in subjects with type 2 diabetes: a randomized trial.
Tuttolomondo A · Cardiovascular diabetology · 2021
Randomized controlled trial · 10 results
- Analysis of efficacy and safety of dulaglutide 0.75 mg stratified by sex in patients with type 2 diabetes in 2 randomized, controlled phase 3 studies in Japan.
Onishi Y · Endocrine journal · 2017
Randomized controlled trial · 12 results
- Efficacy and Safety of Dulaglutide in Older Patients: A post hoc Analysis of the REWIND trial.
Riddle MC · The Journal of clinical endocrinology and metabolism · 2021
Randomized controlled trial · 8 results
- Gastrointestinal Tolerability of Once-Weekly Dulaglutide 3.0 mg and 4.5 mg: A Post Hoc Analysis of the Incidence and Prevalence of Nausea, Vomiting, and Diarrhea in AWARD-11.
Van J · Diabetes therapy : research, treatment and education of diabetes and related disorders · 2021
Randomized controlled trial · 10 results
- EFFICACY AND SAFETY OF DULAGLUTIDE IN HISPANIC/LATINO PATIENTS WITH TYPE 2 DIABETES IN THE AWARD CLINICAL PROGRAM.
Davidson JA · Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2016
Randomized controlled trial · 8 results
- Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes.
Guo L · Nature · 2026
Randomized controlled trial · 16 results
- Efficacy and safety of once-weekly efpeglenatide in people with suboptimally controlled type 2 diabetes: The AMPLITUDE-D, AMPLITUDE-L and AMPLITUDE-S randomized controlled trials.
Aroda VR · Diabetes, obesity & metabolism · 2023
Randomized controlled trial · 13 results
- Effect of Orally Administered Semaglutide Versus Dulaglutide on Diabetes-Related Quality of Life in Japanese Patients with Type 2 Diabetes: The PIONEER 10 Randomized, Active-Controlled Trial.
Ishii H · Diabetes therapy : research, treatment and education of diabetes and related disorders · 2021
Randomized controlled trial · 14 results
- Pharmacokinetics, Pharmacodynamics, and Safety of Dulaglutide After Single or Multiple Doses in Chinese Healthy Subjects and Patients with T2DM: A Randomized, Placebo-Controlled, Phase I Study.
Xu J · Advances in therapy · 2022
Randomized controlled trial · 19 results
- Glycaemic efficacy of an expanded dose range of dulaglutide according to baseline glycated haemoglobin (HbA1c) subgroup: Post hoc analysis of AWARD-11.
Frias JP · Diabetes, obesity & metabolism · 2021
Randomized controlled trial · 10 results
- Glycaemic variability in patients with type 2 diabetes mellitus treated with dulaglutide, with and without concomitant insulin: Post hoc analyses of randomized clinical trials.
Jódar E · Diabetes, obesity & metabolism · 2022
Randomized controlled trial · 9 results
- Metabolic Abnormalities Following Tirzepatide Monotherapy in Japanese Patients with Type 2 Diabetes: A Phase 3 SURPASS J-mono Post Hoc Analysis.
Onishi Y · Diabetes therapy : research, treatment and education of diabetes and related disorders · 2024
Randomized controlled trial · 9 results
- Insulin Sensitivity and Beta Cell Function With Macupatide Alone or With Dulaglutide in Type 2 Diabetes: A Phase 1b, Randomised Controlled Trial.
Heise T · Diabetes, obesity & metabolism · 2026
Randomized controlled trial · 16 results
- Safety and efficacy of switching from dulaglutide to tirzepatide across clinically relevant baseline characteristics in participants with T2D: subgroup analysis of SURPASS-SWITCH.
Violante-Ortiz R · BMJ open diabetes research & care · 2026
Randomized controlled trial · 10 results
- Glucose-lowering effects of semaglutide compared with dulaglutide using professional continuous glucose monitoring in outpatients with type 2 diabetes mellitus: a pilot study.
Kurozumi A · Diabetology international · 2023
Non-randomized trial · 20 results
- Effects of GLP-1 agonists on 10-year cardiovascular risk reduction in primary prevention: A 44-week open label prospective study.
Seijas-Amigo J · Diabetes & metabolic syndrome · 2025
Non-randomized trial · 9 results
- Dulaglutide and Kidney Function-Related Outcomes in Type 2 Diabetes: A REWIND Post Hoc Analysis.
Botros FT · Diabetes care · 2023
Non-randomized trial · 3 results
- Treatment Satisfaction and Quality of Life with Tirzepatide Versus Dulaglutide Among Japanese Patients with Type 2 Diabetes: Exploratory Evaluation of the SURPASS J-mono Trial.
Ishii H · Diabetes therapy : research, treatment and education of diabetes and related disorders · 2023
Non-randomized trial · 22 results
- Appetite, eating attitudes, and eating behaviours during treatment with retatrutide in adults with type 2 diabetes: Results of a phase 2 study.
Kanu C · Diabetes, obesity & metabolism · 2025
Non-randomized trial · 11 results
- Assessment of Pancreas Safety in the Development Program of Once-Weekly GLP-1 Receptor Agonist Dulaglutide.
Nauck MA · Diabetes care · 2017
Non-randomized trial · 7 results
- Weight loss in patients with type 2 diabetes receiving once-weekly dulaglutide plus insulin lispro or insulin glargine plus insulin lispro: A post-hoc analysis of the AWARD-4 study across baseline body mass index subgroups.
Fuechtenbusch M · Diabetes, obesity & metabolism · 2019
Non-randomized trial · 14 results
- Subgroup analysis of phase 3 studies of dulaglutide in Japanese patients with type 2 diabetes.
Onishi Y · Endocrine journal · 2016
Non-randomized trial · 5 results
- Efficacy and Safety of Once-Weekly Dulaglutide in Elderly Chinese Patients with Type 2 Diabetes: A Post Hoc Analysis of AWARD-CHN Studies.
Kuang J · Diabetes therapy : research, treatment and education of diabetes and related disorders · 2020
Non-randomized trial · 13 results
- A 1-year safety study of dulaglutide in Japanese patients with type 2 diabetes on a single oral hypoglycemic agent: an open-label, nonrandomized, phase 3 trial.
Emoto M · Endocrine journal · 2015
Non-randomized trial · 17 results
- Efficacy and safety analyses across 4 subgroups combining low and high age and body mass index groups in Japanese phase 3 studies of dulaglutide 0.75 mg after 26 weeks of treatment.
Hamano K · Endocrine journal · 2017
Non-randomized trial · 16 results
- Dulaglutide Effect on Proteins Associated With CKD Progression.
McFarlin BE · Kidney international reports · 2026
Non-randomized trial · 17 results
- Dulaglutide and Glomerular Hyperfiltration, Proteinuria, and Albuminuria in Youth With Type 2 Diabetes: Post Hoc Analysis of the AWARD-PEDS Study.
Bjornstad P · Diabetes care · 2024
Non-randomized trial · 3 results
- A novel approach to patients with schizophrenia and type 2 diabetes showing low treatment compliance
Argitis P · European psychiatry : the journal of the Association of European Psychiatrists · 2022
Non-randomized trial · 2 results
- Low body mass index and old age are useful in predicting the hemoglobin A1c-lowering effect of switching from sitagliptin to dulaglutide in Japanese patients with type 2 diabetes mellitus: a single-center, open-label, single-arm, pilot study.
Iwasaki T · Diabetology international · 2018
Non-randomized trial · 7 results
- Improved glycemic control with once-weekly dulaglutide in addition to insulin therapy in type 2 diabetes mellitus patients on hemodialysis evaluated by continuous glucose monitoring.
Yajima T · Journal of diabetes and its complications · 2018
Non-randomized trial · 6 results
- Effects of Semaglutide Versus Dulaglutide on Epicardial Fat Thickness in Subjects with Type 2 Diabetes and Obesity.
Iacobellis G · Journal of the Endocrine Society · 2020
Non-randomized trial · 8 results
- The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists.
Urva S · Diabetes, obesity & metabolism · 2020
Non-randomized trial · 9 results
- A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes.
Barrington P · Diabetes, obesity & metabolism · 2011
Non-randomized trial · 11 results
- Clinical Pharmacokinetics of Dulaglutide in Patients with Type 2 Diabetes: Analyses of Data from Clinical Trials.
Geiser JS · Clinical pharmacokinetics · 2016
Non-randomized trial · 10 results
- Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programme.
Yu M · Diabetes, obesity & metabolism · 2016
Non-randomized trial · 6 results
- Treatment satisfaction in people with type 2 diabetes mellitus treated with once-weekly dulaglutide: data from the AWARD-1 and AWARD-3 clinical trials.
Reaney M · Diabetes, obesity & metabolism · 2015
Non-randomized trial · 9 results
- No Dose Adjustment is Recommended for Digoxin, Warfarin, Atorvastatin or a Combination Oral Contraceptive When Coadministered with Dulaglutide.
de la Peña A · Clinical pharmacokinetics · 2017
Non-randomized trial · 11 results
- Effect of once-weekly dulaglutide versus insulin glargine in people with type 2 diabetes and different baseline glycaemic patterns: A post hoc analysis of the AWARD-2 clinical trial.
Giorgino F · Diabetes, obesity & metabolism · 2019
Non-randomized trial · 2 results
- Efficacy and Safety of Dulaglutide by Baseline HbA1c in Chinese Patients with Type 2 Diabetes: A Post Hoc Analysis.
Yu M · Diabetes therapy : research, treatment and education of diabetes and related disorders · 2020
Non-randomized trial · 10 results
- HbA1c Reduction in Dulaglutide-Treated Patients Irrespective of Duration of Diabetes, Microvascular Disease, and BMI: A Post Hoc Analysis From the REWIND Trial.
Kwan AYM · Diabetes care · 2022
Non-randomized trial · 5 results
- Reduction of Hepatic Fat Content by Dulaglutide for the Treatment of Diabetes Mellitus: A Two-Centre Open, Single-Arm Trial.
Liu C · Endocrinology, diabetes & metabolism · 2025
Non-randomized trial · 12 results
- Effect of expanded dulaglutide weekly doses (3.0 mg and 4.5 mg) on cardiovascular disease risk factors in participants with type 2 diabetes at increased cardiovascular disease risk: a post hoc analysis of the AWARD-11 study.
Cox DA · Diabetes, obesity & metabolism · 2022
Non-randomized trial · 9 results
- Efficacy of Dulaglutide in Chinese Patients with Type 2 Diabetes and Different Glycemic Patterns: a Post-hoc Analysis of the Phase 3 AWARD-CHN2 Trial.
Li Q · Diabetes therapy : research, treatment and education of diabetes and related disorders · 2022
Non-randomized trial · 7 results
- Comparative cardiovascular outcomes of semaglutide to dulaglutide in patients with type 2 diabetes.
Kishimori T · Scientific reports · 2025
Observational study · 8 results
- Comparative Effectiveness of Tirzepatide Versus Dulaglutide or Semaglutide on Major Cardiovascular Events in Type 2 Diabetes and Cardiovascular Disease: Insights From Two Target-Trial Emulations.
Ostrominski JW · Diabetes care · 2026
Observational study · 8 results